ClinConnect ClinConnect Logo
Search / Trial NCT02707497

The Effect of REcombinant Human Thrombopoietin (rhTPO) on Sepsis Patients With aCUte Severe thrombocytopEnia

Launched by RUILAN WANG · Mar 11, 2016

Trial Information

Current as of November 13, 2025

Recruiting

Keywords

Sepsis Severe Thrombocytopenia Recombinant Human Thrombopoietin Platelets 28 Day Mortality

ClinConnect Summary

This clinical trial is investigating whether a treatment called recombinant human thrombopoietin (rhTPO) can help patients with sepsis who also have very low platelet levels, a condition known as thrombocytopenia. The study aims to see if rhTPO can quickly increase platelet counts, help patients recover faster, reduce the need for blood transfusions, and ultimately lower the risk of dying within 28 days. This is important because sepsis can cause serious complications, and low platelet counts can make recovery even harder.

To participate in this trial, patients must be between 65 and 74 years old with a confirmed infection and a specific level of organ dysfunction. They should also have very low platelet counts (less than 50,000 per microliter of blood). However, individuals with certain medical histories, such as recent chemotherapy or serious organ issues, are not eligible. Those who join the trial can expect close monitoring and support from the medical team while they receive rhTPO treatment, and their progress will be tracked throughout the study.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Confirmed or clinical diagnosed infection
  • 2. The change of Sequential Organ Failure Assessment(ΔSOFA) score ≥ 2
  • 3. PLT\< 50×10\^9/L
  • 4. Informed consent
  • Exclusion Criteria:
  • 1. History of the treatments with chemotherapeutic drugs or heparin within six months
  • 2. History of bone marrow stem cell disorders, malignancy, or immunologic diseases
  • 3. History of bone marrow, lung, liver, kidney, pancreas, or small bowel transplantation.
  • 4. Confirmed End-stage renal failure(GFR \<10ml/min,Scr\>707μmol/L)
  • 5. Confirmed Disseminated Intravascular Coagulation(DIC)
  • 6. Confirmed Hemorrhagic brain injury or need craniocerebral operation
  • 7. Died anticipated within 24 hours
  • 8. Known pregnancy or at breastfeeding

About Ruilan Wang

Ruilan Wang is a dedicated clinical trial sponsor with a strong commitment to advancing medical research and improving patient outcomes. With a focus on innovative therapies and cutting-edge treatments, Ruilan Wang collaborates with leading research institutions and healthcare professionals to design, implement, and oversee clinical trials that adhere to the highest ethical and scientific standards. The organization emphasizes robust data integrity and patient safety, ensuring that all trials contribute valuable insights to the medical community. Ruilan Wang's expertise in regulatory compliance and a patient-centric approach positions it as a trusted partner in the pursuit of transformative healthcare solutions.

Locations

Shanghai, Shanghai, China

Patients applied

0 patients applied

Trial Officials

Ruilan Wang, MD,PhD

Principal Investigator

The department of ICU, Shanghai General Hospital, Shanghai Jiaotong University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials